Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stögbauer Jakob, Schegerer Victoria, Berger Fabian K, Schulz-Schaeffer Walter, Fassbender Klaus, Naumann Jasmin, Smola Sigrun, Eisenbeis Janina, Bewarder Moritz, Rosar Florian, Kettner Michael, Gilcher Thomas, Diedrich Sabine, Fousse Mathias
Аннотация
BACKGROUND: B-cell-depleting therapies are increasingly being used to treat autoimmune diseases. Although thousands of patients are and have been treated with these agents, the data are not yet strong enough to identify rare side effects with certainty.
METHODS: We report the case of a patient undergoing ocrelizumab therapy for relapsing multiple sclerosis who developed a severe limbic syndrome.
RESULTS: Autoimmune pathogenesis was initially suspected, with worsening on immunosuppressive therapy. Later, after diagnosis of an enterovirus infection, treatment with ribavirin and favipiravir in combination with intravenous immunoglobulins was initiated. After 4 weeks of therapy, the patient's clinical condition had stabilized with residual cognitive deficits.
CONCLUSION: Diagnosis and treatment of enterovirus infections remain challenging, especially in patients receiving immunosuppressive therapy.
METHODS: We report the case of a patient undergoing ocrelizumab therapy for relapsing multiple sclerosis who developed a severe limbic syndrome.
RESULTS: Autoimmune pathogenesis was initially suspected, with worsening on immunosuppressive therapy. Later, after diagnosis of an enterovirus infection, treatment with ribavirin and favipiravir in combination with intravenous immunoglobulins was initiated. After 4 weeks of therapy, the patient's clinical condition had stabilized with residual cognitive deficits.
CONCLUSION: Diagnosis and treatment of enterovirus infections remain challenging, especially in patients receiving immunosuppressive therapy.